Jens Jakob1, Tom Lesluyes2, Anna Simeonova-Chergou3, Frederik Wenz4, Peter Hohenberger5, Frederic Chibon6, Sophie Le Guellec2. 1. Department of General‑, Visceral- and Paediatric Surgery, University Medical Center Göttingen, 37099, Göttingen, Germany. Jens.jakob@med.uni-goettingen.de. 2. Department of Pathology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France. 3. Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Heidelberg, Germany. 4. University Medical Center, University of Freiburg, Freiburg, Germany. 5. Department of Surgery, University Medical Center Mannheim, University of Heidelberg, Heidelberg, Germany. 6. INSERM U1037, Cancer Research Center in Toulouse (CRCT), 31037, Toulouse, France.
Abstract
PURPOSE: CINSARC (Complexity INdex in SARComas) is a prognostic signature for soft tissue sarcoma that determines the risk for recurrence and may serve to guide the decision for adjuvant chemotherapy. The aim of this study was to compare the CINSARC signature of pre- and posttreatment biopsies of sarcoma patients treated within a phase I trial evaluating preoperative sunitinib and irradiation. METHODS: We retrieved 14 pairs of formalin-fixed paraffin-embedded blocks from pretreatment biopsies and posttreatment resection specimens and performed expression profiling of the 67 CINSARC signature genes. RESULTS: In 5/14 patients, both probes were unsuitable for expression analysis because there was no (vital) tissue left in biopsies or resection specimens. Comparing the CINSARC risk classification before and after treatment in the remaining patients, 2/9 shifted from a high- to a low-risk classification for metastatic disease after preoperative treatment with radiation therapy plus sunitinib and 7/9 pairs of pre- and posttreatment biopsies revealed identical results. CONCLUSION: Concurrent radiation therapy and sunitinib leads to diverging results of prognostic gene array testing in a relevant proportion of sarcoma patients. These changes may reflect tumor heterogeneity, local treatment effects, or prognostic changes of the disease. Caution is advised in the selection of samples and interpretation of test results.
PURPOSE: CINSARC (Complexity INdex in SARComas) is a prognostic signature for soft tissue sarcoma that determines the risk for recurrence and may serve to guide the decision for adjuvant chemotherapy. The aim of this study was to compare the CINSARC signature of pre- and posttreatment biopsies of sarcoma patients treated within a phase I trial evaluating preoperative sunitinib and irradiation. METHODS: We retrieved 14 pairs of formalin-fixed paraffin-embedded blocks from pretreatment biopsies and posttreatment resection specimens and performed expression profiling of the 67 CINSARC signature genes. RESULTS: In 5/14 patients, both probes were unsuitable for expression analysis because there was no (vital) tissue left in biopsies or resection specimens. Comparing the CINSARC risk classification before and after treatment in the remaining patients, 2/9 shifted from a high- to a low-risk classification for metastatic disease after preoperative treatment with radiation therapy plus sunitinib and 7/9 pairs of pre- and posttreatment biopsies revealed identical results. CONCLUSION: Concurrent radiation therapy and sunitinib leads to diverging results of prognostic gene array testing in a relevant proportion of sarcoma patients. These changes may reflect tumor heterogeneity, local treatment effects, or prognostic changes of the disease. Caution is advised in the selection of samples and interpretation of test results.
Authors: S G C Kroeze; C Fritz; L Basler; E Gkika; T B Brunner; A L Grosu; M Guckenberger Journal: Strahlenther Onkol Date: 2019-02-08 Impact factor: 3.621
Authors: S Le Guellec; T Lesluyes; E Sarot; C Valle; T Filleron; P Rochaix; T Valentin; G Pérot; J-M Coindre; F Chibon Journal: Ann Oncol Date: 2018-08-01 Impact factor: 32.976
Authors: Penella J Woll; Peter Reichardt; Axel Le Cesne; Sylvie Bonvalot; Alberto Azzarelli; Harald J Hoekstra; Michael Leahy; Frits Van Coevorden; Jaap Verweij; Pancras C W Hogendoorn; Monia Ouali; Sandrine Marreaud; Vivien H C Bramwell; Peter Hohenberger Journal: Lancet Oncol Date: 2012-09-04 Impact factor: 41.316
Authors: A Willner; K Fechner; A Agaimy; F Haller; M Eckstein; O J Ott; F Putz; U S Gaipl; S Kersting; N Meidenbauer; R Grützmann; R Fietkau; S Semrau Journal: Strahlenther Onkol Date: 2021-11-04 Impact factor: 3.621